Newsroom

Sorted by: Latest

-

NASDAQ: ENSG Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages The Ensign Group, Inc. (NASDAQ: ENSG) Investors to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by The Ensign Group, Inc. (NASDAQ: ENSG) on behalf of investors who purchased or acquired The Ensign Group, Inc. securities and experienced significant financial losses. ENSG Accused of Nursing Home Deficiencies On June 8, 2026, Hunterbrook Media published a report entitled “Ensign: The N...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Looking to Buy or Sell in Maine? This York-Based Team Just Ranked #1 in Maine on RealTrends

YORK, Maine--(BUSINESS WIRE)--Williams Realty Partners ranked #1 in Maine by sales volume and #2 by sides among large teams in the 2026 RealTrends Verified rankings....
-

Elevance Health Makes Clinical Review Faster, More Connected with Health OS

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health today announced advancements in how it helps streamline clinical review and create a simpler, faster, and more connected experience for care providers and members through Health OS. Health OS is Elevance Health’s secure data platform designed to connect health information across electronic health records (EHRs), labs, and health information exchanges, helping support more informed and timely clinical decisions while reducing administrative burden f...
-

Rapalogix Health Closes $20 Million Series A Financing to Accelerate Re-Q Health Expansion and Advance Prescription Therapeutics Pipeline

CARLSBAD, Calif.--(BUSINESS WIRE)--Rapalogix Health, a biotechnology company advancing a science-first approach to cellular longevity and skin health, today announced the closing of a $20 million Series A financing co-led by GordonMD Global Investments® LP (“GordonMD”) — the Beverly Hills-based physician-led biopharma investment firm — and Woodline Partners. The round reflects GordonMD’s conviction that mechanism-driven platforms in dermatology represent a compelling and underserved frontier in...
-

Clutch Health Selects Enigma Networks to Strengthen Cyber Resilience in the Age of AI

PHILADELPHIA--(BUSINESS WIRE)--Enigma Networks®, the pioneer of Zero Trust for Internal Networks (ZTNX), today announced that Clutch Health has selected Enigma AI™ to strengthen continuous security monitoring, automate security operations, and streamline compliance reporting across its AI-powered patient engagement and loyalty platform. The selection comes as threat actors increasingly weaponize AI to accelerate attacks – from automated vulnerability discovery to highly targeted impersonation a...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Resumen: One Biosciences obtiene financiación BOOST del Paris-Saclay Cancer Cluster para desarrollar el primer ensayo unicelular para terapias con ADC

PARÍS--(BUSINESS WIRE)--One Biosciences, empresa pionera en perfiles tumorales unicelulares de grado clínico que combina biotecnología e inteligencia computacional, ha anunciado hoy que ha recibido financiación a través de una subvención BOOST del Paris-Saclay Cancer Cluster (PSCC) para desarrollar el primer ensayo unicelular destinado a terapias oncológicas basadas en conjugados anticuerpo-fármaco (ADC). El rápido crecimiento de los ADC hace cada vez más necesarias estrategias de biomarcadores...